In a major boost for India’s generics industry, the Delhi High Court has ruled that Macleods Pharmaceuticals may continue its ...

UK pharma major GSK has entered an agreement to acquire 35Pharma Inc, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based ...

Australian biotech Neurizon (ASX: NUZ) has dosed the first participant with NUZ-001 in Regimen I of the US-based HEALEY ALS Platform Trial, launching a key Phase II/III study in amyotrophic lateral ...

Ireland headquartered Alkermes (Nasdaq: ALKS) has announced that Richard Pops will retire from his role as chief executive (CEO), effective July 31, 2026.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Eylea (aflibercept 8mg, 114.3 ...

US pharma giant Pfizer (NYSE: PFE) has struck a commercialization deal with China’s Sciwind Biosciences for the GLP-1 drug Xianyida (ecnoglutide), gaining exclusive rights in mainland China in a pact ...

Japan’s Astellas Pharma and USA-based Vir Biotechnology have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN dual-masked CD3 T-cell engager (TCE) ...

ViiV Healthcare, the HIV specialist majority owned by GSK, has announced week 96 and end of study results from the Phase I/II IMPAACT 2017 study, the first trial to evaluate a complete injectable long ...

Privately-held US firm Abcuro has announced topline results from the Phase II/III MUSCLE study of ulviprubart (ABC008).

US pharma major AbbVie’s $100 billion agreement with the US administration signals a structural recalibration of drug pricing negotiations, tying tariff exemptions and pricing flexibility directly to ...

Latin American specialty pharma company SteinCares has signed a licensing agreement with India’s Shilpa Biologicals to commercialize a biosimilar across Latin America, marking the Indian group’s first ...

The US Food and Drug Administration (FDA) has granted full approval to pharma giant Pfizer’s Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and fluorouracil-based ...